FUTURE OF HEALTHCARE
Radius XR | November 17, 2022
Today at the CES Unveiled New York event, Radius XR™, a new fashion-forward wearable healthcare technology brand, was named a CES® 2023 Innovation Awards Honoree in both the Digital Health and Virtual & Augmented Reality categories.
Radius was selected from among a record number of submissions to this year’s CES Innovation Awards program. The announcement was made ahead of CES 2023, the influential technology event, happening Jan. 5-8 in Las Vegas, NV.
Radius XR builds on the therapeutic legacy of IrisVision, a leader in digital vision technologies and itself a 2019 CES Innovation Winner. The Radius proprietary XR assistive device brings together—for the first time—multimodal diagnostics, practice management, and patient engagement.
“This is a tremendous honor for our new company. It follows on the success of our IrisVision visual assistive device, which has provided a life-changing solution for thousands of individuals living with legal blindness and low-vision conditions. Radius expands on our commitment to vision health by providing the eyecare industry with an easy-to-use wearable device capable of performing standard perimetry tests. Other exams include color vision, visual acuity, contrast sensitivity—a comprehensive suite of standard vision tests. Development of additional exams is ongoing.”
Radius founder and CEO Ammad Khan
Radius enables patients to quickly and easily conduct vision tests with minimal guidance or intervention by the staff. The device’s RadiusExam® software and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards. “By designing our own hardware and software, we’re able to overcome many of the challenges inherent in the off-the-shelf headsets already on the market. Matching visual field strategies, background luminance, stimulus size and dynamic range allows us to mirror the current standards, making it easy and intuitive for clinicians to transition to Radius,” said John Trefethen, Radius Chief Marketing Officer.
In addition, the included Business Suite helps clinicians manage everyday aspects critical to their practice's ongoing success. Features like patient education, staff training and clinician onboarding are now possible inline with the Radius platform.
Radius is the industry’s lightest wearable device and has the look and feel of a pair of stylish sunglasses. The compact, lightweight design overcomes the challenges of expensive and bulky legacy devices that force patients to sit in uncomfortable positions for testing. With Radius, exams can be conducted anywhere, even in the waiting room, eliminating the need to shuttle patients between machines, which can be challenging for individuals with mobility or vision issues.
The CES Innovation Awards program, owned and produced by the Consumer Technology Association (CTA)®, is an annual competition honoring outstanding design and engineering in 27 consumer technology product categories. Those with the highest rating receive the “Best of Innovation” distinction. An elite panel of industry expert judges, including members of the media, designers, engineers and more, reviewed submissions based on innovation, engineering and functionality, aesthetics, and design.
The CES 2023 Innovation Awards honorees, including product descriptions and photos, can be found at CES.tech/innovation. Radius will be on display at the Innovation Awards Showcase at CES 2023 in Las Vegas in January.
About Radius XR
The Radius XR platform is a portable vision diagnostic and patient engagement system that combines medical-grade diagnostics, business management, and patient education tools in a single wearable XR device. The RadiusExam® and proprietary algorithms provide diagnostic testing results equivalent to current exam gold standards, with the clinical science validated by Deming regression. As the algorithm presents stimuli to patients, it adapts to responses to maximize the algorithm's speed.
The total hardware and software system helps medical professionals diagnose patients with accuracy, grow their eyecare practices, enhance patient engagement, and reduce staff workload by enabling patients to perform self-guided vision exams with minimal supervision.
HEALTH TECHNOLOGY, MEDICAL DEVICES
19Labs | December 20, 2022
In cooperation with the Ministry of Health and the Georgetown Public Hospital Corporation a telemedicine pilot program with GALE eClinics was launched in four remote areas of Guyana.
"We have reached a milestone and begin a journey that has the potential to transform health."
Dr. Leslie Ramsammy, GPHC Board Chairman
During the Telemedicine Launch, 19Labs CEO, Ram Fish, joined Guyana's Health Minister, Dr. Frank Anthony, in Masakenari, or as it is better known locally, Gunns Village. They were welcomed by the village Toshao, Paul Chekema, and the village residents. Using the newly installed eClinic system, Gunns was able to connect to the Georgetown Public Hospital and the three other villages that form part of this pilot program.
The program's purpose is to provide equitable healthcare to all of Guyana's citizens. This keeps in line with the vision of Guyana's President, Dr. Ali, of creating a 'world-class' healthcare system for Guyana. Dr. Ramsammy, began the launch by saying:
"Our ambition is to improve health care for all of our people, and as we understand that we can't put…a Georgetown public-level hospital in every village, we believe that citizens, in every part of the country, could get access to basic healthcare…We have reached a stage this morning, where we could launch Guyana's national telemedicine program."
One of the major challenges in achieving such a vision is the remote locations with the lack of connectivity. Gunns Village is a 5-day boat and land trek during the rainy season when planes cannot use the local airstrip. 19Labs is proud to provide a solution as the four health posts that are part of this pilot are now connected to the world through the internet over satellite.
With the GALE eClinic Telemedicine units, even the most isolated village now has access to top-quality medical care. In a very short time, Gunns went from an area that had no connectivity, electricity, and little medical equipment, to the ability to instantly connect to the healthcare and staff of the Georgetown Public Hospital. Dr. Anthony said:
"With the technology we have now installed, this particular health center has a full complement of internet-enabled devices which we will…be able to do ultrasounds, ECGs, and a whole host of other things to help to assess the patient."
GALE eClinics replicate the full clinical experience providing and filling the need for both general health and specialty care including prenatal, OBGYN, maternal, cardiac, and chronic condition management. Our partnership goes beyond a one-time fix. The local communities now have access to more opportunities. Ram Fish said:
"This goes even beyond just health care, [this transforms communities]. The equity that it brings to us also opens the eyes of people and places to different cultures, and different ways of doing things…It's about empowering with technology local young women and men who really become the centers of the communities beyond just health…This is the beginning of a journey…We will expand and work together to really make healthcare equitable across Guyana and beyond."
19Labs is the creator of GALE, Next Generation Point-of-Care platform for pharmacies, schools, and rural communities. GALE brings together cutting-edge diagnostic technologies from industry leaders like Zoom, Elo, Amwell, Eko, Samsung Mobile, MIR, Omron, Viasat, and many others in one smart, efficient, and cost-effective platform. It was designed from the ground up to be operated by non-healthcare professionals, in locations with limited infrastructure and optimized for low bandwidth and intermittent connectivity.
DIGITAL HEALTHCARE, MEDICAL DEVICES
Swisslog Healthcare | December 19, 2022
Swisslog Healthcare, a leading supplier in healthcare technology solutions of both medication management and transport automation, has appointed Cory Kwarta as its CEO. Kwarta, who was appointed as CEO of the Swisslog Healthcare – TransLogic division earlier this year, is now entrusted to oversee the global organization, guiding both the company’s TransLogic® and Medication Management divisions.
“Since I started at Swisslog Healthcare, my goal has always been to help improve efficiencies in the healthcare industry. As CEO of the company, I will remain dedicated to our organization’s commitment of helping our customers and partners provide the highest quality healthcare.”
Cory Kwarta was also recently named as a member of Swisslog Healthcare’s Board of Directors. The move came as a result of Kwarta’s recent prior promotion to CEO of Swisslog Healthcare – TransLogic and his 15 years of service with the organization.
Kwarta has a bachelor’s degree in systems engineering from the United States Military Academy at West Point and a master’s degree in business administration from the University of Denver.
Swisslog Healthcare’s TransLogic division works with healthcare facilities to develop custom-designed pneumatic tube systems which automate their needs to transport materials from station to station. The Medication Management division of Swisslog Healthcare assists healthcare facilities with automating and managing the pharmaceutical workflow, including preparation, patient-specific dosing, delivery, and storage. Both divisions deliver operational cost reduction by enabling the redeployment of personnel to patient-facing activities.
About Swisslog Healthcare
Swisslog Healthcare provides integrated medication supply chain solutions to hospitals and health systems to assist providers in treating patients across the continuum of care. Integrating transport and pharmacy automation, value-added services, and intelligent software, Swisslog Healthcare enables healthcare providers to respond to patient’s needs quickly and with greater accuracy. The company minimizes many sources of operational waste, so providers achieve higher levels of productivity to impact the well-being of patients in positive ways.
DIGITAL HEALTHCARE, MEDICAL DEVICES
Sharps Technology Inc | December 21, 2022
Sharps Technology, Inc. an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces they have commenced manufacturing of their much-needed ultra-low waste smart safety syringe products in their European operation in Hungary. The plant has been producing products and will begin shipments to support the distribution and sales agreement with Nephron Pharmaceuticals by the end of the year, and customer agreements in Europe in early 2023. The production of these specialty syringe products will ramp up over the next several months to increase supply.
Sharps innovative syringe designs provide a beneficial set of features and advantages for the healthcare industry. These syringe product features include a combination of ultra-low waste, passive and active safety, and reuse prevention. By combining all these features and building them into a portfolio of syringe offerings, it will create product platforms that can help drive down the cost of healthcare treatments.
“This is a transformative point for our company as we move from a pre-revenue research & development start-up to a true manufacturing company that should generate revenue in the first half of 2023. Today’s healthcare providers are responsible for managing their supply chains and driving down their total cost of ownership (TCO) for medical treatments. Sharps Technology will be able to offer products that can directly support those programs. At Sharps Technology, we feel that by using better drug delivery technology, we can help create additional medical treatments at no additional cost for patients that need them."
Robert Hayes, Sharps Technology CEO
"We look forward to a bright future at Sharps Technology," concluded Mr. Hayes. "The recently signed distribution agreement with Nephron Pharmaceuticals accelerates the sales plan for our innovative syringe products that are currently being produced in the Sharps plant in Hungary. The ability to pull forward our sales plan for customers in the US will create a unique opportunity for early revenue at Sharps. We expect to have our first products available for sale in the US by the end of January 2023, with additional products to be added to the distribution network by mid-year of 2023."
When healthcare providers use ultra-low waste syringes with multi-dose vials, it allows for the availability of up to 20% to 40% more medication for patients that need the treatment. This medication availability is created by using more efficient syringes designated as low-waste and ultra-low waste products, and not trapping medication within the syringe after the dose is given. The use of standard syringes that are not designated as low waste or ultra-low waste products typically creates a dead space area within the syringe where excess medication is trapped and cannot be used. This dead space then causes the healthcare provider to throw away the unused medication. The trapped medication in the dead space of a standard syringe can waste as much as 100 microliters of medication or more. The Pharmaceutical companies that fill their medication into vials understand this and must then overfill the vial with drug therapy to compensate for the problem. As the costs for medication and medical treatments rise, the discarded medication can cost the industry millions of dollars, or more, globally.
The purchase of the European facility was finalized in the summer of 2022 and Sharps has invested in infrastructure and equipment upgrades to prepare the plant for a full manufacturing schedule. Syringe products produced by Sharps comply with all applicable FDA and ISO requirements and have been awarded the European Union’s CE Mark. The Sharps Hungary team, led by General Manager Filippo Filippi, brings together a dedicated and knowledgeable manufacturing force, with more than 20 years of experience in supplying the world with high quality, innovative syringe products. Prior to the GM position, Filippi’s career spanned years of building, managing, and supporting multiple manufacturing sites across Europe, Asia, and Africa. The Hungary plant is vertically integrated in that it has the capability to manufacture the syringe components by injection molding, assemble the devices on automated lines or by manual assembly if required, and to sterilize the products on-site through the Ethylene Oxide sterilization process. This last stage of the syringe manufacturing process is unique in the industry and gives Sharps an advantage in supporting shortened lead times as compared to the common need to utilize a third-party for sterilization. The plant has manufacturing capacity to supply more than 50 million units today and the facility could be expanded to produce 250 million units or more over the next couple of years.
About Sharps Technology
Sharps Technology is a medical device and pharmaceutical packaging company specializing in the development and manufacturing of innovative drug delivery systems. The company’s product lines focus on low waste and ultra-low waste syringe technologies that incorporate both passive and active safety features. These features protect front line healthcare workers from life-threatening needle stick injuries and protect the public from needle re-use. Sharps Technology has extensive expertise in specialized prefilled syringe systems and ready to use processing. The company has a manufacturing facility in Hungary and has partnered with Nephron Pharmaceuticals to expand its manufacturing capacity in the US..